Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/15/2023 | Buy → Hold | Jefferies | |
| 12/15/2023 | $30.00 → $1.50 | Buy → Neutral | H.C. Wainwright |
| 12/14/2023 | Buy → Neutral | Ladenburg Thalmann | |
| 12/14/2023 | $23.00 → $1.45 | Buy → Underperform | BofA Securities |
| 12/14/2023 | Outperform → Mkt Perform | William Blair | |
| 12/14/2023 | $28.00 → $3.00 | Outperform → Neutral | Robert W. Baird |
| 12/14/2023 | $25.00 → $4.00 | Overweight → Neutral | Piper Sandler |
8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares
Gainers Akanda (NASDAQ:AKAN) shares rose 177.7% to $0.37 during Friday's pre-market session. The company's market cap stands at $11.7 million. Scorpius Holdings (AMEX:SCPX) stock increased by 28.17% to $0.13. The market value of their outstanding shares is at $4.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 27.0% to $0.15. The market value of their outstanding shares is at $5.7 million. ZimVie (NASDAQ:ZIMV) shares moved upwards by 23.61% to $20.99. The company's market cap stands at $572.7 million. Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 17.16% to $0.17. The market value of their outstanding shares is at $6.6 million. As per the press release, Q
The Dow Jones index closed lower by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw bought a total of 1,210 shares at an average price of $1.12. To acquire these shares, it cost around $1,355. What's Happening: On May 15,
SC 13D/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
SC 13G/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
Leerink Partners downgraded Reneo Pharmaceuticals from Outperform to Market Perform
Jefferies downgraded Reneo Pharmaceuticals from Buy to Hold
H.C. Wainwright downgraded Reneo Pharmaceuticals from Buy to Neutral and set a new price target of $1.50 from $30.00 previously
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company's Board of Directors. "Roshawn is an accomplished leader within the biopharma industry," said Mike Grey, Executive Chairman of Reneo Pharmaceuticals. "Her extensive experience in healthcare reimbursement, policy, and patient access will be an invaluable addition to Reneo as we plan for commercialization of REN001 in the U.S. and Europe. We look forward to working with Roshawn o
IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Mr. Hoelscher, Kenneth Harrison, Partner at Novo Ventures (US) Inc., resigned from the Reneo Board of Directors. Reneo also today announced that Lon Cardon, Ph.D. will not seek
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker symbol "OKUR" commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR) ("OnKure"), a clinical-stage biopharmaceutical company focused on the develo
– Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo's stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. ("OnKure"). The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from "Reneo Pharmaceut
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights On May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the "Merger").The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure's portfolio of precision oncology therapies.The Merger a